JPS5225013A - Insulin pharmaceutical for nasal administration - Google Patents

Insulin pharmaceutical for nasal administration

Info

Publication number
JPS5225013A
JPS5225013A JP51055965A JP5596576A JPS5225013A JP S5225013 A JPS5225013 A JP S5225013A JP 51055965 A JP51055965 A JP 51055965A JP 5596576 A JP5596576 A JP 5596576A JP S5225013 A JPS5225013 A JP S5225013A
Authority
JP
Japan
Prior art keywords
nasal administration
insulin pharmaceutical
insulin
pharmaceutical
nasal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP51055965A
Other languages
Japanese (ja)
Other versions
JPS6030651B2 (en
Inventor
Shinichiro Hirai
Toshiaki Ikenaga
Etsu Matsuzawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of JPS5225013A publication Critical patent/JPS5225013A/en
Publication of JPS6030651B2 publication Critical patent/JPS6030651B2/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PURPOSE: A novel insulin solution capable of self-medication of insulin by nasal administration..
COPYRIGHT: (C)1977,JPO&Japio
JP51055965A 1975-08-20 1976-05-14 Insulin preparations for nasal administration Expired JPS6030651B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB34576/75 1975-08-20
GB34576/75A GB1527605A (en) 1975-08-20 1975-08-20 Insulin preparation for intranasal administration

Publications (2)

Publication Number Publication Date
JPS5225013A true JPS5225013A (en) 1977-02-24
JPS6030651B2 JPS6030651B2 (en) 1985-07-17

Family

ID=10367351

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51055965A Expired JPS6030651B2 (en) 1975-08-20 1976-05-14 Insulin preparations for nasal administration

Country Status (5)

Country Link
JP (1) JPS6030651B2 (en)
BE (1) BE841871A (en)
DE (1) DE2620446A1 (en)
FR (1) FR2321275A1 (en)
GB (1) GB1527605A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5145405A (en) * 1974-10-16 1976-04-17 Unyusho Kowan Gijutsu Kenkyush JIBAN KAIRYOKOHO
JPS53115509A (en) * 1977-12-19 1978-10-09 Kitagawa Iron Works Co Method of changing weak ground into stable ground
JPS53115510A (en) * 1977-12-19 1978-10-09 Kitagawa Iron Works Co Support structure made by hardening weak soil
JPS59112925A (en) * 1982-12-10 1984-06-29 シンテツクス（ユ−・エス・エ−・）インコ−ポレイテイド Nasal administration composition
JPS6289627A (en) * 1985-06-04 1987-04-24 Chugai Pharmaceut Co Ltd Anemic remedy for nasotracheal administration
JPH02213522A (en) * 1989-02-14 1990-08-24 Kajima Corp Construction method for base of structure
WO2012096276A1 (en) * 2011-01-13 2012-07-19 株式会社カネカ Percutaneous absorption promoter and external skin preparation

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2917535C2 (en) * 1979-04-30 1986-10-30 Hoechst Ag, 6230 Frankfurt Insulin solutions resistant to denaturation
WO1983000288A1 (en) * 1981-07-17 1983-02-03 Balschmidt, Per A stable aqueous, therapeutic insulin preparation and a process for preparing it
CH657779A5 (en) * 1982-10-05 1986-09-30 Sandoz Ag GALENIC COMPOSITIONS CONTAINING CALCITONIN.
AU572815B2 (en) * 1982-12-29 1988-05-19 Armour Pharmaceutical Company Pharmaceutical calcitonin compositions for intranasal application
JPS59163313A (en) * 1983-03-09 1984-09-14 Teijin Ltd Peptide hormone composition for nasal administration
US4548922A (en) * 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
DE3443877A1 (en) * 1984-06-09 1985-12-12 Hoechst Ag Insulin preparations, process for their preparation, and their use
US4658830A (en) * 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
CA1274774A (en) * 1985-04-15 1990-10-02 Kenneth S. Su Method for administering insulin
AU584184B2 (en) * 1985-04-15 1989-05-18 Eli Lilly And Company An improved method for administering insulin
US4731360A (en) * 1985-08-16 1988-03-15 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US4692441A (en) * 1985-08-16 1987-09-08 Merck & Co., Inc. Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
DK179286D0 (en) * 1986-04-18 1986-04-18 Nordisk Gentofte INSULIN PREPARATION
CA1291036C (en) * 1986-04-23 1991-10-22 Edwin I. Stoltz Nasal administration of drugs
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
CA1335076C (en) * 1987-04-01 1995-04-04 Hanna R. Kowarski Pharmaceutical composition and method for intranasal administration
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
US6645504B1 (en) 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Pharmaceutical oral, enteral or by-inhalation dosage form for suppressing an autoimmune response associated with type i diabetes
JPH04126437U (en) * 1991-05-10 1992-11-18 八木アンテナ株式会社 optical receiver
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5338837A (en) * 1991-12-13 1994-08-16 The Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making same
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
JPH08511234A (en) * 1993-02-23 1996-11-26 ザ トラスティーズ オブ プリンストン ユニヴァーシティー Solution and solid phase formation of glycosidic bonds
US5639866A (en) * 1993-02-23 1997-06-17 Princeton University Single-step formation of multiple glycosidic linkages
IS1796B (en) * 1993-06-24 2001-12-31 Ab Astra Inhaled polypeptide formulation composition which also contains an enhancer compound
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
KR100419037B1 (en) 1994-03-07 2004-06-12 넥타르 테라퓨틱스 Methods of delivery of insulin through the lungs and their composition
US6165976A (en) * 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
JP3687993B2 (en) * 1994-06-24 2005-08-24 シスメックス株式会社 Insulin standard solution
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
ATE236617T1 (en) 1994-12-22 2003-04-15 Astrazeneca Ab AEROSOL MEDICINAL FORMULATIONS
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
DE10114178A1 (en) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinc-free and low-zinc insulin preparations with improved stability
US6653492B2 (en) 2001-05-02 2003-11-25 Novo Nordick A/S Preparation of bile acids
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
DE10227232A1 (en) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Sour insulin preparations with improved stability
KR101820024B1 (en) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 Combination of an insulin and a GLP-1 agonist
HUE037735T2 (en) 2009-11-13 2018-09-28 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION COMPRISING desPro36Exendin-4(1-39)-Lys6-NH2 AND METHIONINE
ES2534191T3 (en) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
BR112013004756B1 (en) 2010-08-30 2020-04-28 Sanofi Aventis Deutschland use of ave0010 for the manufacture of a medication for the treatment of type 2 diabetes mellitus
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
RU2650616C2 (en) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Pharmaceutical combination for use in glycemic control in patients with type 2 diabetes mellitus
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
JP6970615B2 (en) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Insulin glargine / lixisenatide fixed ratio prescription
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL62232C (en) * 1900-01-01
US3096249A (en) * 1960-05-10 1963-07-02 Samuel J Prigal Emulsion composition

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5145405A (en) * 1974-10-16 1976-04-17 Unyusho Kowan Gijutsu Kenkyush JIBAN KAIRYOKOHO
JPS5416325B2 (en) * 1974-10-16 1979-06-21
JPS53115509A (en) * 1977-12-19 1978-10-09 Kitagawa Iron Works Co Method of changing weak ground into stable ground
JPS53115510A (en) * 1977-12-19 1978-10-09 Kitagawa Iron Works Co Support structure made by hardening weak soil
JPS59112925A (en) * 1982-12-10 1984-06-29 シンテツクス（ユ−・エス・エ−・）インコ−ポレイテイド Nasal administration composition
JPS6289627A (en) * 1985-06-04 1987-04-24 Chugai Pharmaceut Co Ltd Anemic remedy for nasotracheal administration
JPH02213522A (en) * 1989-02-14 1990-08-24 Kajima Corp Construction method for base of structure
WO2012096276A1 (en) * 2011-01-13 2012-07-19 株式会社カネカ Percutaneous absorption promoter and external skin preparation
JP5906194B2 (en) * 2011-01-13 2016-04-20 株式会社カネカ Skin preparation

Also Published As

Publication number Publication date
JPS6030651B2 (en) 1985-07-17
BE841871A (en) 1976-11-16
DE2620446A1 (en) 1977-03-03
GB1527605A (en) 1978-10-04
FR2321275B1 (en) 1979-04-13
FR2321275A1 (en) 1977-03-18

Similar Documents

Publication Publication Date Title
JPS5225013A (en) Insulin pharmaceutical for nasal administration
CA1027005A (en) Inhaler for powdered medicament
GB1554157A (en) Stable insulin preparation for intra nasal administration
JPS5241214A (en) Method of making preparations for oral administration
JPS51139617A (en) A process for preparing a remedy for intestinal infectious diseases
JPS5228922A (en) Medicine mixture for animals
AU504182B2 (en) Pharmaceutical dosage forms
JPS52108028A (en) Remedies for dysacousis
JPS5228926A (en) Process for film coating of medicines
GR61158B (en) N-tetrahydrofurfuryl-noroxymorphone,salts thereof by addition of acid,pharmaceutical mediums containing them and process for the preparation thereof
JPS51123815A (en) A process for preparing coated solid medicines
JPS52128232A (en) Drugs for alleviating toxicity to kidneys
JPS5228946A (en) Amino acid infusion
JPS545046A (en) Cephalosporin preparation for oral administration
JPS51136818A (en) Method for preparing stable prostaglandine pharma ceuticals
JPS51151387A (en) Process for preparing 2-alpha-maltosyl -maltosyl glucose
JPS5214779A (en) Novel process for preparing pericyazine
JPS5241210A (en) Method of making insulin preparations for rectal administration
JPS5217499A (en) Preparation of mappicine
JPS5569510A (en) Carcinostatic agent
JPS5212919A (en) A method for preparing a stable prostaglandin f2alpha injection
JPS5498339A (en) Carcinostatic agent
JPS5225017A (en) Process for preparing a pharmaceutical for rectal administration
JPS5251362A (en) Preparation of optically active pyrrolidine derivatives
JPS5215808A (en) Process for preparing a drug against athlet s foot